Aisa Pharma
Pre-clinicalAisa Pharma is developing AISA-021 to treat primary and secondary Raynaud’s in patients with Systemic Sclerosis (or Scleroderma).
Founded
2018
Focus
Small Molecules
About
Aisa Pharma is developing AISA-021 to treat primary and secondary Raynaud’s in patients with Systemic Sclerosis (or Scleroderma).
Company Info
TypePrivate
Founded2018
LocationSan Diego, United States
StagePre-clinical
Contact
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile